Q1 2015 13F Holders as of 3/31/2015
-
Type / Class
-
Equity / Common Stock, $0.0001 Par Value Per Share
-
Shares outstanding
-
108M
-
Number of holders
-
74
-
Total 13F shares, excl. options
-
17M
-
Shares change
-
+4.68M
-
Total reported value, excl. options
-
$405M
-
Value change
-
+$112M
-
Number of buys
-
53
-
Number of sells
-
-14
-
Price
-
$23.88
Significant Holders of Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) as of Q1 2015
77 filings reported holding ITCI - Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share as of Q1 2015.
Intra-Cellular Therapies, Inc. - Common Stock, $0.0001 Par Value Per Share (ITCI) has 74 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 17M shares
of 108M outstanding shares and own 15.73% of the company stock.
Largest 10 shareholders include FMR LLC (5.24M shares), BlackRock Advisors LLC (1.13M shares), WASATCH ADVISORS INC (1M shares), BlackRock Fund Advisors (977K shares), Visium Asset Management, LP (976K shares), ADAGE CAPITAL PARTNERS GP LLC (700K shares), Redmile Group, LLC (669K shares), VANGUARD GROUP INC (630K shares), BlackRock Institutional Trust Company, N.A. (461K shares), and FRANKLIN RESOURCES INC (367K shares).
This table shows the top 74 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.